QSP Modeling to Inform Dose & Regimen Selection for TAK-280: A Bi-specific Antibody

2:00 pm - Thursday 17th September 2026

  • Both QW and BIW dosing led to comparable predicted safety outcome
  • Immune cell dynamics reveal the key role of de-sensitization in driving attenuation of cytokine Cmax

Speakers:

Scientist
Takeda Pharmaceutical